Share Price and Basic Stock Data
Last Updated: February 14, 2026, 10:21 pm
| PEG Ratio | 5.94 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fischer Medical Ventures Ltd operates within the Chemicals – Inorganic – Others sector, with its stock currently priced at ₹42.0 and a market capitalization of ₹2,706 Cr. The company’s revenue trajectory has shown variability, with reported sales of ₹21 Cr for the year ended March 2024, rising significantly to ₹111 Cr by March 2025, and a trailing twelve-month (TTM) revenue of ₹171 Cr. This growth reflects a robust recovery from a zero-revenue position in March 2023. Quarterly sales figures indicate a marked increase in performance, particularly in September 2025, where sales peaked at ₹86 Cr, followed by ₹101 Cr in December 2025. However, the absence of sales in some quarters, such as September 2023, suggests potential operational challenges that the company must address to ensure consistent revenue generation.
Profitability and Efficiency Metrics
Fischer Medical Ventures Ltd’s profitability has demonstrated fluctuations, with an operating profit margin (OPM) that stood at 21% as of the latest reporting. The company recorded a net profit of ₹19 Cr for the year ending March 2025, indicating a significant recovery from a net loss of ₹0 Cr in March 2023. Despite this improvement, the return on equity (ROE) remained relatively low at 0.70%, while the return on capital employed (ROCE) was reported at 1.08%. The company’s interest coverage ratio (ICR) of 9.80x suggests it can comfortably meet its interest obligations. Nevertheless, the cash conversion cycle (CCC) of 205 days in March 2025 indicates inefficiencies in working capital management, particularly when compared to industry norms, which typically range from 30 to 90 days for companies in the chemicals sector.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fischer Medical Ventures Ltd reflects a mixed financial position. Total assets stood at ₹468 Cr as of September 2025, with reserves amounting to ₹295 Cr and borrowings of ₹30 Cr, suggesting a manageable debt level. The company’s equity capital increased from ₹0.17 Cr in March 2023 to ₹64 Cr by March 2025. The price-to-book value (P/BV) ratio is notably high at 16.97x, indicating that the market has high expectations for future growth, although it may also imply overvaluation. Additionally, the current ratio of 3.59x and quick ratio of 3.50x indicate a strong liquidity position, providing a buffer against short-term liabilities. However, the company’s high P/E ratio of 68.4 raises concerns about sustainability, especially in light of its low net profit margins.
Shareholding Pattern and Investor Confidence
Fischer Medical Ventures Ltd’s shareholding pattern reveals a significant shift in ownership structure, with promoters holding 61.80% of the equity as of December 2025, down from a peak of 74.91% in June 2024. This dilution may reflect a strategic decision to attract institutional investors, with foreign institutional investors (FIIs) holding 4.85% and domestic institutional investors (DIIs) at 1.36%. The public shareholding stood at 31.99%, indicating a healthy level of retail investor participation, with the number of shareholders increasing to 22,920. This diverse ownership base may enhance investor confidence, although the declining promoter stake could raise questions about long-term commitment. The market will closely watch how these dynamics affect governance and strategic direction moving forward.
Outlook, Risks, and Final Insight
Fischer Medical Ventures Ltd is positioned for potential growth, driven by increasing sales and improving profitability metrics. However, the company faces several risks, including operational inefficiencies reflected in its cash conversion cycle and the high P/BV ratio, which may indicate overvaluation. Additionally, fluctuations in the shareholding structure could lead to uncertainties regarding management’s strategic priorities. The company must focus on enhancing operational efficiencies and stabilizing revenue streams to sustain investor confidence. In scenarios where the company successfully addresses these risks, it could leverage its strong market position to capture growth opportunities. Conversely, failure to improve operational metrics may hinder its ability to attract further investment and achieve long-term profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,678 Cr. | 41.3 | 125/33.1 | 67.7 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 13.8 Cr. | 27.6 | 42.9/24.3 | 41.8 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 209 Cr. | 267 | 356/236 | 14.2 | 211 | 2.99 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 7,025 Cr. | 569 | 728/408 | 38.4 | 157 | 0.53 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 346 Cr. | 442 | 494/376 | 14.6 | 144 | 0.68 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 4,753.13 Cr | 380.79 | 100.54 | 156.25 | 0.50% | 13.95% | 10.65% | 6.18 |
Quarterly Result
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 | 101 |
| Expenses | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 | 80 |
| Operating Profit | 0 | 3 | -0 | 0 | 0 | 2 | 4 | 16 | 22 |
| OPM % | 12% | -2% | 1% | 3% | 5% | 18% | 19% | 21% | |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 | 21 |
| Tax % | 6% | 271% | -38% | 350% | 28% | 51% | 19% | 9% | |
| Net Profit | 0 | 3 | -0 | 0 | -0 | 1 | 5 | 14 | 19 |
| EPS in Rs | 0.00 | 0.05 | -0.00 | 0.01 | -0.01 | 0.02 | 0.08 | 0.21 | 0.30 |
Last Updated: February 2, 2026, 12:16 am
Below is a detailed analysis of the quarterly data for Fischer Medical Ventures Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 101.00 Cr.. The value appears strong and on an upward trend. It has increased from 86.00 Cr. (Sep 2025) to 101.00 Cr., marking an increase of 15.00 Cr..
- For Expenses, as of Dec 2025, the value is 80.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 70.00 Cr. (Sep 2025) to 80.00 Cr., marking an increase of 10.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Sep 2025) to 22.00 Cr., marking an increase of 6.00 Cr..
- For OPM %, as of Dec 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Sep 2025) to 21.00%, marking an increase of 2.00%.
- For Other Income, as of Dec 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Sep 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Dec 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 1.00 Cr..
- For Depreciation, as of Dec 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Sep 2025) to 21.00 Cr., marking an increase of 4.00 Cr..
- For Tax %, as of Dec 2025, the value is 9.00%. The value appears to be improving (decreasing) as expected. It has decreased from 19.00% (Sep 2025) to 9.00%, marking a decrease of 10.00%.
- For Net Profit, as of Dec 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Sep 2025) to 19.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 0.30. The value appears strong and on an upward trend. It has increased from 0.21 (Sep 2025) to 0.30, marking an increase of 0.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:44 am
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | 0 | 21 | 111 | 171 |
| Expenses | 0 | 19 | 108 | 147 |
| Operating Profit | 0 | 2 | 3 | 23 |
| OPM % | 11% | 9% | 3% | 14% |
| Other Income | -0 | 0 | 1 | 10 |
| Interest | 0 | 0 | 0 | 2 |
| Depreciation | -0 | 0 | 2 | 2 |
| Profit before tax | -0 | 2 | 2 | 29 |
| Tax % | 13% | 45% | ||
| Net Profit | -0 | 2 | 1 | 20 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.30 |
| Dividend Payout % | -0% | -0% | 22% |
YoY Net Profit Growth
| Year | 2024-2025 |
|---|---|
| YoY Net Profit Growth (%) | -50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% |
Fischer Medical Ventures Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2024-2025 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 428% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 78% |
| 5 Years: | 91% |
| 3 Years: | 149% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | -0 | 28 | 274 | 295 |
| Borrowings | 1 | 2 | 85 | 30 |
| Other Liabilities | 0 | 4 | 34 | 77 |
| Total Liabilities | 0 | 86 | 457 | 468 |
| Fixed Assets | 0 | 15 | 24 | 31 |
| CWIP | 0 | 0 | 1 | 2 |
| Investments | 0 | 1 | 11 | 121 |
| Other Assets | 0 | 70 | 421 | 313 |
| Total Assets | 0 | 86 | 457 | 468 |
Below is a detailed analysis of the balance sheet data for Fischer Medical Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 295.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2025) to 295.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 85.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 55.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 77.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 468.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 457.00 Cr. (Mar 2025) to 468.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 110.00 Cr..
- For Other Assets, as of Sep 2025, the value is 313.00 Cr.. The value appears to be declining and may need further review. It has decreased from 421.00 Cr. (Mar 2025) to 313.00 Cr., marking a decrease of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 468.00 Cr.. The value appears strong and on an upward trend. It has increased from 457.00 Cr. (Mar 2025) to 468.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (295.00 Cr.) exceed the Borrowings (30.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
Free Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Free Cash Flow | -1.00 | 0.00 | -82.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Debtor Days | 345 | 398 | 251 |
| Inventory Days | 36 | ||
| Days Payable | 82 | ||
| Cash Conversion Cycle | 345 | 398 | 205 |
| Working Capital Days | 324 | 498 | 107 |
| ROCE % | 5% | 1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.08 | 1.65 | -2.12 |
| Diluted EPS (Rs.) | 0.08 | 1.08 | -2.12 |
| Cash EPS (Rs.) | 0.52 | 0.37 | -2.12 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 52.90 | 15.16 | -15.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 52.90 | 15.16 | -15.47 |
| Revenue From Operations / Share (Rs.) | 17.35 | 3.92 | 10.44 |
| PBDIT / Share (Rs.) | 0.75 | 0.44 | 0.88 |
| PBIT / Share (Rs.) | 0.50 | 0.40 | 0.88 |
| PBT / Share (Rs.) | 0.42 | 0.39 | -0.07 |
| Net Profit / Share (Rs.) | 0.26 | 0.34 | -2.12 |
| NP After MI And SOA / Share (Rs.) | 0.18 | 0.34 | -2.12 |
| PBDIT Margin (%) | 4.36 | 11.25 | 8.46 |
| PBIT Margin (%) | 2.89 | 10.38 | 8.46 |
| PBT Margin (%) | 2.44 | 10.06 | -0.72 |
| Net Profit Margin (%) | 1.53 | 8.75 | -20.33 |
| NP After MI And SOA Margin (%) | 1.09 | 8.75 | -20.33 |
| Return on Networth / Equity (%) | 0.35 | 2.26 | 0.00 |
| Return on Capital Employeed (%) | 0.90 | 2.64 | 4.97 |
| Return On Assets (%) | 0.26 | 2.12 | -10.32 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -2.15 |
| Total Debt / Equity (X) | 0.17 | 0.00 | -2.15 |
| Asset Turnover Ratio (%) | 0.40 | 0.48 | 0.00 |
| Current Ratio (X) | 3.59 | 18.37 | 5.18 |
| Quick Ratio (X) | 3.50 | 17.20 | 5.18 |
| Inventory Turnover Ratio (X) | 16.23 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 9.80 | 34.92 | 0.92 |
| Interest Coverage Ratio (Post Tax) (X) | 4.43 | 28.19 | -1.21 |
| Enterprise Value (Cr.) | 5536.85 | 3303.93 | 1.98 |
| EV / Net Operating Revenue (X) | 50.02 | 157.47 | 11.03 |
| EV / EBITDA (X) | 1145.02 | 1399.44 | 130.31 |
| MarketCap / Net Operating Revenue (X) | 51.74 | 159.28 | 8.05 |
| Price / BV (X) | 16.97 | 41.20 | -5.43 |
| Price / Net Operating Revenue (X) | 51.74 | 159.31 | 8.05 |
| EarningsYield | 0.00 | 0.00 | -0.02 |
After reviewing the key financial ratios for Fischer Medical Ventures Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 1.65 (Mar 24) to 0.08, marking a decrease of 1.57.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 1.08 (Mar 24) to 0.08, marking a decrease of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.52, marking an increase of 0.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.90. It has increased from 15.16 (Mar 24) to 52.90, marking an increase of 37.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.90. It has increased from 15.16 (Mar 24) to 52.90, marking an increase of 37.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 17.35. It has increased from 3.92 (Mar 24) to 17.35, marking an increase of 13.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 2. It has increased from 0.44 (Mar 24) to 0.75, marking an increase of 0.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.50, marking an increase of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.39 (Mar 24) to 0.42, marking an increase of 0.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.26, marking a decrease of 0.08.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.18, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 4.36. This value is below the healthy minimum of 10. It has decreased from 11.25 (Mar 24) to 4.36, marking a decrease of 6.89.
- For PBIT Margin (%), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 10. It has decreased from 10.38 (Mar 24) to 2.89, marking a decrease of 7.49.
- For PBT Margin (%), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 10. It has decreased from 10.06 (Mar 24) to 2.44, marking a decrease of 7.62.
- For Net Profit Margin (%), as of Mar 25, the value is 1.53. This value is below the healthy minimum of 5. It has decreased from 8.75 (Mar 24) to 1.53, marking a decrease of 7.22.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 8. It has decreased from 8.75 (Mar 24) to 1.09, marking a decrease of 7.66.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 15. It has decreased from 2.26 (Mar 24) to 0.35, marking a decrease of 1.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 10. It has decreased from 2.64 (Mar 24) to 0.90, marking a decrease of 1.74.
- For Return On Assets (%), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 5. It has decreased from 2.12 (Mar 24) to 0.26, marking a decrease of 1.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.17, marking an increase of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.48 (Mar 24) to 0.40, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has decreased from 18.37 (Mar 24) to 3.59, marking a decrease of 14.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 2. It has decreased from 17.20 (Mar 24) to 3.50, marking a decrease of 13.70.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 16.23. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 16.23, marking an increase of 16.23.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.80. This value is within the healthy range. It has decreased from 34.92 (Mar 24) to 9.80, marking a decrease of 25.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.43. This value is within the healthy range. It has decreased from 28.19 (Mar 24) to 4.43, marking a decrease of 23.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,536.85. It has increased from 3,303.93 (Mar 24) to 5,536.85, marking an increase of 2,232.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 50.02. This value exceeds the healthy maximum of 3. It has decreased from 157.47 (Mar 24) to 50.02, marking a decrease of 107.45.
- For EV / EBITDA (X), as of Mar 25, the value is 1,145.02. This value exceeds the healthy maximum of 15. It has decreased from 1,399.44 (Mar 24) to 1,145.02, marking a decrease of 254.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.28 (Mar 24) to 51.74, marking a decrease of 107.54.
- For Price / BV (X), as of Mar 25, the value is 16.97. This value exceeds the healthy maximum of 3. It has decreased from 41.20 (Mar 24) to 16.97, marking a decrease of 24.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.31 (Mar 24) to 51.74, marking a decrease of 107.57.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fischer Medical Ventures Ltd:
- Net Profit Margin: 1.53%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.9% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.35% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.5
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 67.7 (Industry average Stock P/E: 100.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.53%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Survey No. 480/2 AP Medtech Zone, Nadupura Village, Vishakapatnam Andhra Pradesh 530032 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ravindran Govindan | Chairman & Managing Director |
| Ms. Svetlana Rao | Whole Time Executive Director |
| Mr. Sanjay Jayantilal Jain | Independent Director |
| Mr. Jaya Ankur Singhania | Independent Director |
| Mr. Khairy Jamaluddin Abu Bakkar | Independent Director |
| Mr. Roberto M Pagdanganan | Independent Director |
FAQ
What is the intrinsic value of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd's intrinsic value (as of 14 February 2026) is ₹2.34 which is 94.33% lower the current market price of ₹41.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,678 Cr. market cap, FY2025-2026 high/low of ₹125/33.1, reserves of ₹295 Cr, and liabilities of ₹468 Cr.
What is the Market Cap of Fischer Medical Ventures Ltd?
The Market Cap of Fischer Medical Ventures Ltd is 2,678 Cr..
What is the current Stock Price of Fischer Medical Ventures Ltd as on 14 February 2026?
The current stock price of Fischer Medical Ventures Ltd as on 14 February 2026 is ₹41.3.
What is the High / Low of Fischer Medical Ventures Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fischer Medical Ventures Ltd stocks is ₹125/33.1.
What is the Stock P/E of Fischer Medical Ventures Ltd?
The Stock P/E of Fischer Medical Ventures Ltd is 67.7.
What is the Book Value of Fischer Medical Ventures Ltd?
The Book Value of Fischer Medical Ventures Ltd is 5.55.
What is the Dividend Yield of Fischer Medical Ventures Ltd?
The Dividend Yield of Fischer Medical Ventures Ltd is 0.01 %.
What is the ROCE of Fischer Medical Ventures Ltd?
The ROCE of Fischer Medical Ventures Ltd is 1.08 %.
What is the ROE of Fischer Medical Ventures Ltd?
The ROE of Fischer Medical Ventures Ltd is 0.70 %.
What is the Face Value of Fischer Medical Ventures Ltd?
The Face Value of Fischer Medical Ventures Ltd is 1.00.